COVID-19: impact of vaccination in myeloma patients.

Hoornaert, E; Dachy, F; Hansenne, A; Bailly, S; van Maanen, A; Gruson, D; Vekemans, M-C

Hoornaert, E; Dachy, F; Hansenne, A; Bailly, S; van Maanen, A; Gruson, D; Vekemans, M-C.

Hoornaert E; Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint Luc, 10 avenue Hippocrate, 1200 Woluwe Saint Lambert, Brussels, Belgium. Ellen.hoornaert@uclouvain.be.
Dachy F; Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.
Hansenne A; Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.
Bailly S; Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.
van Maanen A; Statistical Support Unit, King Albert II Institute, Cliniques Universitaires Saint Luc, 1200, Brussels, Belgium.
Gruson D; Department of Laboratory Medicine, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.
Vekemans MC; Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium.

Ann Hematol ; 101(7): 1607-1608, 2022 07.

Article in English | MEDLINE | ID: covidwho-1782784

Subject(s)

COVID-19; Multiple Myeloma; COVID-19/prevention & control; Dendritic Cells; Humans; Multiple Myeloma/therapy; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Myeloma Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Ann Hematol Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: S00277-022-04799-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google